FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis

  • End date
    May 19, 2023
  • participants needed
  • sponsor
    Guangdong Provincial Hospital of Traditional Chinese Medicine
Updated on 19 May 2021
mucinous adenocarcinoma
treatment regimen
gastric adenocarcinoma
endoscopic biopsy


In this study, patients with advanced gastric adenocarcinoma whose peritoneal metastasis and peritoneal nodule pathologically confirmed metastasis and/or exfoliative cytology were confirmed as the clinical stage of peritoneal metastasis, who had not received treatment before, were invited to participate in the study.To evaluate the surgical conversion rate and tumor regression grade (TRG grade) of patients with stage gastric cancer with peritoneal metastasis using docetaxel, oxaliplatin, fluorouracil (FLOT regimen) combined with teriprizumab (PD-1).


The study drugs in this study are docetaxel, oxaliplatin, 5-FU, leucovorin, tigio capsules and teriprizumab.

Dosage and dosing regimen for all research phases:

The enrolled patients will receive 4 cycles of FLOT regimen + teriprizumab treatment before surgery, and every 2 weeks is a treatment cycle (Q2W). The specific plan is as follows.

  • FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W
  • Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W If the transformation is successful, the patient undergoes R0 surgical resection of D2 lymph node dissection for gastric cancer in accordance with the "Japanese Gastric Cancer Treatment Guidelines. Physician's Edition. 4th Edition". After the operation, the patient will continue to receive 4 cycles of FLOT treatment + Teripril Anti-treatment, the treatment plan is the same as before.

After completing the 4 cycles of treatment, oral Tiggio Capsule (S-1) and Teriprizumab were maintained for 1 year. The specific plan is as follows.

  • Tiggio capsule (S-1) 40-60mg (BSA<1.25 m2: 40mg, 1.25 m2BSA1.5 m2: 50mg, BSA> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;
  • Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year.

Condition Gastropathy, treatment with medication, medication therapy, Gastric Cancer, pharmacotherapies, Gastric Carcinoma, cancer chemotherapy, drug therapy, Stomach Discomfort, gastric cancers, Stomach Cancer, drug therapies, chemotherapy regimen, pharmacological treatment, Chemotherapy, chemotherapy regimens
Treatment FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)
Clinical Study IdentifierNCT04886193
SponsorGuangdong Provincial Hospital of Traditional Chinese Medicine
Last Modified on19 May 2021


Yes No Not Sure

Inclusion Criteria

Informed consent of the patient
18 years old <age <80 years old
The primary gastric lesion was diagnosed as gastric adenocarcinoma by endoscopic biopsy histopathology (papillary adenocarcinoma pap, tubular adenocarcinoma tub, mucinous adenocarcinoma muc, signet ring cell carcinoma sig, poorly differentiated adenocarcinoma por)
The clinical stage of laparoscopic exploration is peritoneal metastasis, peritoneal nodule pathologically confirmed metastasis and/or exfoliated cytology test positive for advanced gastric cancer patients
Preoperative ECOG [Using the ECOG scoring standard Zubrod-ECOG-WHO (ZPS, 5-point method) developed by the Eastern Cooperative Oncology Group (ECOG)] Physical State Score 0/1
Preoperative anesthesia risk score sheet (ASA score sheet) I-III

Exclusion Criteria

The pathology of the peritoneal nodule confirmed no metastasis, and the exfoliated cytology test was negative
Pregnant or lactating women
Suffer from severe mental illness
Preoperative imaging or intraoperative exploration revealed that there have been distant blood metastases in the liver, lungs, and brain
A history of other malignant diseases within 5 years
A history of allergies to any component of teriprizumab, docetaxel, oxaliplatin, and fluorouracil
A history of continuous systemic corticosteroid therapy within 1 month
Complications of gastric cancer (bleeding, perforation, obstruction) requiring emergency surgery
A history of unstable angina or myocardial infarction, or a history of cerebral infarction or cerebral hemorrhage within 6 months, and a lung function test FEV1 <50% of the expected value
Have received any of the following treatments
Have received anti-PD-1 or anti-PD-L1 antibody therapy in the past
Have received any investigational drug treatment within 4 weeks before using the drug for the first time
Enroll in another clinical study at the same time, unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up
Receive the last dose of anti-cancer treatment (including radiotherapy) within 4 weeks before the first use of the study drug
Those who have been vaccinated with anti-tumor vaccines or the study drugs have been vaccinated with live vaccines within 4 weeks before the first administration
Those who have undergone major surgery or trauma within 4 weeks before using the study drug for the first time
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note